Peptide Regulatory Tracker
Current US legal status and honest evidence level for every peptide we cover, grouped by whether it is FDA-approved, legal to buy over the counter, or not approved for human use. We update this the moment the record changes.
Last reviewed 2026-08-19.
An FDA advisory panel recommended six peptides, against the FDA’s own reviewers
23 and 24 July 2026. Sources re-verified 2026-08-19.
Nothing became approved and nothing became legal. A committee recommendation is advice to the FDA, not a decision by it.
On 23 and 24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the Section 503A bulks list, the list that governs what a compounding pharmacy is permitted to prepare against a prescription. It voted to recommend six of them: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. The seventh, emideltide (also known as DSIP), was voted down. The vote is advisory and non-binding, and nothing about what is legal changed on the day.
The panel went against the FDA's own reviewers, whose briefing document for that meeting concluded that "a balancing of the criteria weighs against BPC-157 (free base) and BPC-157 acetate being placed on that list." Adding any substance to the 503A list still needs formal rulemaking and sign-off from the Secretary of Health and Human Services, so the statuses in the table below are unchanged by the vote.
The full write-up, with what the human evidence does and does not show and every primary source, is on the peptide hub.
FDA-approved medicines
Legal to buy today
Investigational (in clinical trials)
Not approved for human use
Commonly confused, not actually a peptide
Epitalon is not listed: its human-trial citations could not be independently verified in this research pass, so it is held pending sourcing rather than published unverified.
Looking for what each one does, the benefits and the risks? See the full peptide hub.